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Background and aim. Research on hepatitis B virus (HBV) infection in vivo has been limited due to the absence of a suitable
animal model. We have developed a human–mouse radiation chimera in which normal mice, preconditioned by lethal total
body irradiation and radioprotected with SCID mouse bone marrow cells, are permissive for engraftment of human
hematopoietic cells and solid tissues. This resulting human–mouse model, which comprises three genetically disparate
sources of tissue, is therefore termed Trimera. This study was aimed at assessing the effect of human IL-6 on HBV infection
in vivo in Trimera mice.
Methods. Trimera mice were transplanted with human liver tissue fragments or with HepG2-derived cell lines, which had
been previously infected ex vivo with HBV in the presence or absence of human interleukin-6 (hIL-6) and in the presence of
anti-IL-6-neutralizing antibodies.
Results. HBV sequences appeared in the sera of animals in which the liver tissue was incubated with both HBV and hIL-6
prior to transplantation. A similar result was obtained when a human hepatoblastoma cell line (HepG2), expressing the hIL-6
receptor, was infected ex vivo with HBV in the presence of hIL-6 prior to their injection into spleens of Trimera mice. However,
when liver fragments were infected ex vivo and simultaneously treated with neutralizing antibodies against hIL-6 or were
incubated with HBV prior to transplantation without hIL-6, the rate of mice positive for HBV DNA in their sera was lower.
Human mononuclear cells are also permissive for HBV infection in vitro: in the presence of hIL-6 the infection of these cells
is enhanced; and this infection is suppressed by the chimeric protein named Hyper-IL-6, generated by the fusion of hIL-6 to
the soluble hIL-6 receptor (sIL-6Ra, gp80).Conclusion. hIL-6 facilitates HBV infection in vitro and in vivo. © 2000 Academic Press
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Hepatitis B virus (HBV) infection in humans can cause
chronic liver disease, which may in some cases
progress to hepatocellular carcinoma. The initial steps of
HBV attachment to cells and the targeting of the viral
genome to the host cell nucleus have yet to be eluci-
dated. Thus, a specific receptor for HBV has not been
identified, even though various serum proteins and cel-
lular membrane glycoproteins have been suggested to
mediate cell penetration or viral receptor, respectively.
HBV envelope proteins were reported to contain resi-
dues capable of interacting with polymerized albumin
(Pontisso et al., 1981) enabling virus penetration into
cells via their respective receptors, probably in a non-
specific manner. HBV-related proteins interact with hu-
man serum proteins, as reported by Neurath et al. (1992),
1 To whom correspondence and reprint requests should be ad-
ressed at Goldyne Savad Institute of Gene Therapy, Hadassah Uni-
ersity Hospital, Ein-Kerem, POB 12000, Jerusalem 91120, Israel. Fax:
972-2-6430982. E-mail: galun@md2.huji.ac.il.
299showing that human interleukin-6 (hIL-6) binds to the
pre-S1 (aa 21–47) segment of the HBV envelope. Putative
candidates for HBV receptors, including annexin V (Her-
togs et al., 1993), apolipoprotein H (Mehdi et al., 1994),
and asialoglycoprotein receptor (Treichel et al., 1994),
have recently been reported. Binding experiments dem-
onstrated that the pre-S1 region of the viral envelope
protein contains a recognition site for the host cell
(Neurath et al., 1986; Petit et al., 1990, 1992). Although
previous studies have suggested that HepG2 cells
(Bchini et al., 1991) and human hepatocytes (Galle et al.,
1994; Gripon et al., 1988, 1993; Ochiya et al., 1989) could
support HBV infection in vitro, no cellular receptor has
yet been defined in either system.
Previous investigations conducted in an attempt to
establish HBV infection in small animal models (Taka-
hashi et al., 1995; Walter et al., 1996) resulted in a very
short viremia of a few days, followed by early serocon-
version with the development of anti-HBs antibodies.
Alternative models for chronic HBV viremia using trans-
genic mice, expressing the complete HBV genome, as a
transgene, were constructed (Guidotti et al., 1995). Al-
0042-6822/00 $35.00
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300 GALUN ET AL.though such transgenic animals are an important tool for
understanding the biology of the virus and the effect of
various components of the immune systems in the in-
flammatory reaction in the liver related to HBV infection
(Guidotti et al., 1996), the early steps of infection could
not be assessed in these animals. Infection models have
been established for avian and mammalian members of
the hepadnavirus family other than HBV, in vitro (Tuttle-
man et al., 1986) as well as in vivo (Mason et al., 1983).
However, the viral attachment mechanism of each mem-
ber of this viral family is probably different, as suggested
from genomic comparison (Sprengel et al., 1984) and
reports on the duck hepatitis B virus receptor (Breiner et
al., 1998; Ishikawa et al., 1994; Tong et al., 1999; Urban et
al., 1998) and coreceptor (Li et al., 1996, 1999).
Recently we have shown that normal human liver tissue
that is incubated ex vivo with HBV and then transplanted
under the kidney capsule of Trimera mice can support the
generation of viremia for a number of weeks (Ilan et al.,
1999). The experimental strategy for the development of a
small animal model for HBV infection was based on the
evidence that although the primary infection site for HBV
are hepatocytes, lymphocytes (Korba et al., 1986; Laskus et
al., 1997, 1999; Romet Lemonne et al., 1983), and endothelial
cells (Blum et al., 1983; Mason et al., 1993) have both been
shown to harbor HBV transcripts and viral related proteins
or pre-S1 binding protein (Pontisso et al., 1991), suggesting
a common specific cell membrane receptor mechanism
that supports viral penetration on all three cell types. The
tissue specificity is probably related to the early steps of
infection, as suggested from experiments suggesting that
receptor-negative cells are permissive to HBV replication
following transfection (Galun et al., 1992). All three cell
types that are naturally susceptible to HBV, i.e., hepato-
cytes, lymphocytes, and endothelial cells, also respond to
IL-6 through the human IL-6 receptor (hIL-6R) (Bauer et al.,
1989; Kishimoto et al., 1992; Mackiewicz et al., 1992). In
addition, hIL-6 binds to HBV through pre-S1, as previously
shown (Neurath et al., 1992). Human IL-6 is a member of the
family of four-helical cytokines with pleiotropic biological
effects. In the liver, IL-6 modulates the transcription of
acute-phase response genes and stimulates liver regener-
ation. IL-6 binds to a specific IL-6Ra (gp80) and subse-
quently induces homodimerization of gp130 (IL-6Rb).
We hypothesized that hIL-6 might have a role in HBV
infection, directly or indirectly. In this study we have
employed our HBV Trimera system (Ilan et al., 1999) in
order to investigated the possible role of hIL-6 in HBV
infection.
RESULTS
Human IL-6 supports ex vivo. HBV infection of human
liver in Trimera mice. Human liver tissue fragments were
incubated with HBV DNA-positive sera in the presence of
hIL-6. After infection these fragments were transplanted din Trimera mice. HBV DNA sequences were detected
from day 16 to day 31 posttransplantation in the sera of
about 50% (9/19, animals 14 to 19 were negative and are
not shown in the figure) of the transplanted animals (Fig.
1B). Incubation of liver tissue with hIL-6 prior to ex vivo
HBV infection increased the efficiency of infection to
about 80% (9/11) of transplanted animals (Fig. 1C). In
contrast, animals transplanted with liver tissue frag-
ments incubated ex vivo with HBV-positive sera, in the
bsence of exogenous hIL-6, remained free of detectable
evels of HBV DNA sequences for a period of at least 31
FIG. 1. hIL-6 mediates HBV viremia in SCID . BNX chimeric mice
transplanted with human tissue. PCR amplification products of HBV
precore/core region following DNA extraction from sera of mice, 16 and
31 days after subcapsular kidney transplantation of normal human liver
fragments. The human liver fragments were incubated ex vivo with
human HBV-positive serum prior to transplantation (A) or with HBV
DNA-positive serum and hIL-6 simultaneously (B) or liver fragments
were initially preincubated with hIL-6 and later with HBV (C). In each
section (A to C), the top panel is an EtBr staining, and the bottom panel
shows the results of Southern hybridization analysis of the same gel
using a 32P-labeled HBV DNA probe. The molecular marker size (m) is
indicated by an arrow; numbers at the head of each panel indicate mice
ID No.; 1, positive serum control; and 2, negative serum control.ays posttransplantation (Fig. 1A). The number of ani-
liver fr
s
301HBV INFECTION IN VIVOmals in group A for both day 16 and day 31 in a number
of experiments is over 4; additional experiments are
described in the following sections.
Immunohistochemical analysis revealed that animals,
which contained HBV sequences in their serum at day 31,
also expressed HBsAg in the implanted livers (Fig. 2). It
is hard to determine the exact nature of the cells in which
HBsAg is expressed. According to our previous publica-
tions and unpublished data on hepatitis C virus (HCV)
and HBV infection in Trimera mice it is suggested that
the HBsAg-positive cells are probably hepatocytes. The
absence of detectable HBsAg staining in liver fragments
incubated ex vivo with HBV under the above conditions
and fixed for immunohistochemical analysis prior to
transplantation, i.e., negative controls, indicates that the
HBsAg observed in 31 days posttransplantation in HBV-
positive mice is most likely due to de novo HBsAg syn-
thesis.
Subsequent experiments utilizing over 350 Trimera
mice transplanted with liver fragments, following ex vivo
incubation with HBV-positive serum without addition of
exogenous hIL-6, resulted in an overall infection effi-
FIG. 2. HBsAg staining of an ex vivo HBV incubation of a normal
ubcapsule of SCID . BNX chimeric mice.ciency of 30% (hIL-6 levels in the sera of patients thatwas our source of HBV per infection was in the range of
5 to 120 pg/ml).
To further assess the facilitating role of hIL-6 in HBV
infection, mice sera were analyzed for HBV DNA se-
quences, following infection. Human liver fragments
were infected ex vivo with HBV following short incubation
with hIL-6 and then transplanted under the kidney cap-
sule of the chimeric mice. HBV DNA was measured in
sera of these mice on days 11, 18, and 25 posttransplan-
tation. The addition of hIL-6 increased the rate of infec-
tion by more than 50% compared to the control group
infected without the cytokine, as shown in Fig. 3. This
increase is detectable at days 11 and 18 after transplan-
tation. In long-term experiments, circulating HBV DNA
sequences were detected up to 2 months following
transplantation (data not shown).
The effect of anti-hIL-6 on HBV infection. Figure 3
shows that HBV sequences were detected also in the
group of animals in which the liver fragment was not
incubated with hIL-6 prior to transplantation. One possi-
ble explanation could be the presence of hIL-6 in sera of
HBV-infected patients, which is our viral source for these
agment with hIL-6, 1 month following implantation under the kidneyexperiments. In order to reduce the possible effect of the
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302 GALUN ET AL.intrinsic hIL-6, which could have originated from the HBV
infectious serum and/or the human liver tissue, mice
were transplanted with liver fragments infected with HBV
serum that had been pretreated with a monoclonal anti-
bodies against hIL-6 prior to the incubation with the liver
tissue. In this experimental group of animals, the infec-
tion step was also without the addition of hIL-6. Control
mice were transplanted with HBV-infected liver frag-
ments using the previously described protocol in the
presence of exogenous hIL-6. The results in Fig. 4 show
FIG. 3. Detection of HBV DNA in mice sera at days 12, 18, and 25,
following the transplantation of normal human liver tissue which was
ex vivo incubated with HBV infectious serum in the presence (black
bars) or the absence (gray bars) of hIL-6.
FIG. 4. The effect of anti-hIL-6 on HBV infection in chimeric mice. The
experimental protocol is described in the text. Detection of HBV DNA in
mice sera at days 10, 17, and 24, following the transplantation of normal
human liver tissue which was ex vivo incubated with HBV infectious
serum in the presence of hIL-6 (black bars) or in which the HBV
infectious serum was initially treated with anti-hIL-6-neutralizing mono-h
clonal antibodies and then incubated with the liver tissue in the ab-
sence of hIL-6 (gray bars).that in the presence of antibodies to hIL-6, the infection
rate is reduced. Thus, for this experiment, added hIL-6
increased the efficiency of infection by ;200% for day 10,
;140% for day 17, and ;400% for day 24 posttransplan-
tation, compared to mice transplanted with liver frag-
ments infected with anti-hIL-6-treated virus. In experi-
ments described in Figs. 3 and 4 as well as in all other
experiments described with the “Trimera” system all an-
imals were infected with the same serum and trans-
planted with the same liver tissue.
Detection of HBV ccc DNA in implanted livers prein-
fected with hIL-6 and HBV. The small size of the im-
planted liver fragment restricted our methods for HBV
replication to those techniques combining amplification
steps to detect HBV replication intermediates. Animals
positive for HBV DNA in sera were also analyzed for viral
replication in implanted liver fragments applying specific
primers for HBV ccc DNA. As shown in Fig. 5 HBV ccc
DNA was detected in implants preincubated with HBV
and human IL-6 and only in mice positive for HBV DNA in
serum. The HBV ccc DNA species was not detected in
implants from animals in which HBV DNA was not de-
tected in serum.
Induction of HBV DNA viremia in Trimera mice by
transplantation of HBV-infected HepG2-derived cell lines.
Mice were implanted with HepG2-hIL-6Ra (stably trans-
ected HepG2 cells with hIL-6 receptor a) subsequent to
ncubation with HBV, in the presence of hIL-6. The cells
ere then injected into the spleen of mice and migrated
hrough the portal system to the liver (Fig. 6). HBV DNA
equences were analyzed in serum 13 days after trans-
lantation by PCR. The results of these experiments are
ummarized in Table 1. HBV sequences were not de-
ected in sera of mice that were treated similarly but
ithout hIL-6. Viremia could not be detected also in mice
ransplanted with HepG2-PDI cells (which do not ex-
ress the gp80-binding protein (Ehlers et al., 1994; Rose-
ohn et al., 1993), but do express the gp130 subunit of the
FIG. 5. Detection of HBV ccc DNA in human liver fragments prein-
cubated with hIL-6 and HBV and implanted in Trimera mice. Two weeks
posttransplantation DNA was extracted from fragments, pooled, and
analyzed for the presence of HBV ccc DNA and HBV RC DNA by dot
blot hybridization as described under Material and Methods. Lane 1,
pooled DNA from five grafts harvested from infected Trimera mice; lane
2, pooled DNA from five grafts harvested from noninfected Trimera
mice; lane 3, DNA from intrinsically HBV-infected human liver tissue;
lane 4, DNA from human liver tissue; lane 5, DNA from mouse kidney
tissue.IL-6 receptor (Dittrich et al., 1994). However, in experi-
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303HBV INFECTION IN VIVOments in which HepG2 cells were incubated with HBV in
the presence or absence of hIL-6, HBV DNA sequences
could be detected in mice sera.
The effect of hIL-6 and hyper-IL-6 (HIL-6) on HBV
infection of human mononuclear cells. To further deter-
mine the effect of hIL-6 on HBV infection an additional
human cell lineage was assessed for its permissiveness
for HBV infection in the presence of this cytokine. From
previous studies we had learned that lymphocytes sup-
port HBV infection and also harbor HBV-integrated se-
quences (Korba et al., 1986; Laskus et al., 1997, 1999).
Lymphocytes were also shown to express the IL-6a and
b receptors (Peters et al., 1998). The fact that human
ymphocytes express the human IL-6 receptor and are
ermissive for HBV infection suggested to us that these
ells could be applied to evaluate the role of hIL-6 in viral
ntrance to cells.
Incubation of HBV with human mononuclear cells re-
ulted in the generation of RC HBV DNA from day 4
ostinfection. The highest level of HBV DNA was de-
ected at day 7 and decreased late after, as shown for
oth RC and ccc DNA species. In other experiments we
ere able to detect HBV DNA, RC, and ccc up to 21 days
ollowing infection (data not shown). HBV RC DNA was
etected earlier and the level of HBV ccc DNA was
igher when the virus was incubated with hIL-6 (Fig. 7).
owever, when human mononuclear cells were incu-
ated with HBV in the presence of hyper-hIL-6 (IL6/
IL6Ra fusion protein, Fischer et al., 1997), RC and ccc
HBV DNA viral species were reduced to undetectable
levels. The morphology of the HBV-infected and nonin-
fected human mononuclear cells as well as their number
at each time point was identical for all three groups.
DISCUSSION
In our previous reports, we have shown that Trimera
TABLE 1
HBV DNA Sequences in Sera of Chimeric Mice Following Intra-
plenic Injection of HepG2 and HepG2-Derived Cell Lines Incubated
x Vivo with HBV with or without hIL-6
Cell lines
HepG2 HepG2-IL6-R HepG2-PDI
With (1) or
without (2) hIL-6 1 2 1 2 1 2
HBV DNA Positive 2/2 2/2 4/4 0/2 2/2 0/2
Note. Mice were implanted with HepG2 and HepG2-derived cell
lines subsequent to incubation with HBV in the presence or absence of
hIL-6. Following the ex vivo incubation of the cells, they were injected
into the spleen of mice and migrated through the portal system to the
liver (Fig. 6). HBV DNA sequences were detected in serum 13 days after
transplantation. All parts of the experiment were conducted with the
same HBV infectious serum.mice are permissive for the growth of normal humantissue. Human tissues transplanted into these animals
continue their differentiated state as in the host animal
(Lubin et al., 1991). This advantage was employed for the
development of a HCV infection model in a small animal,
with continuous viral replication for over 2 months (Galun
et al., 1995), and the development of a new HIV infection
model system (Shapira-Nahor et al., 1997). The possible
role of hIL-6 in HBV infection and the potential applica-
tion of the chimeric animal were both suggested in our
recently reported in vivo HBV infection model (Ilan et al.,
999). The present study was aimed to further assess the
otential role of hIL-6 in HBV infection in our HBV small
nimal model.
The effect of hIL-6 on HBV infection is shown in the
xperiments in which HBV was incubated ex vivo with
uman liver fragments and resulted in generation of HBV
equences in the sera of transplanted chimeric animals.
n these animals we were also able to detect a viral
urface protein in the transplanted tissue (Fig. 2). In
ddition, when a hIL-6Ra-expressing cell line were incu-
ated ex vivo with HBV and injected into the spleen of
chimeric animals, HBV sequences were detected in
mouse sera when hIL-6 was present. In all three cell
lines the addition of hIL-6 to cells in the presence of HBV
supported HBV replication (Table 1). Furthermore, anti-
hIL-6-neutralizing monoclonal antibodies reduced the ef-
ficiency of HBV infection. However, we were also able to
detect HBV sequences in some chimeric animals that
were transplanted with liver tissue or injected with
HepG2-derived cells in the absence of exogenous sup-
plementation of hIL-6. Viremia observed in hIL-6-un-
treated animals may result from endogenous hIL-6,
which is naturally present in human sera. The ability of
mAb’s against hIL-6 to reduce the efficiency of infection
supports this conclusion. These results are in agreement
with those previously reported by Bchini et al. (1991), who
showed that sera from HBV DNA-positive patients sup-
ported HBV infection of HepG2 cells in vitro.
In addition to the possible effect of hIL-6 on the infec-
tion of hepatocyte lineage cells with HBV, we had inves-
tigated the role of hIL-6 on HBV infection of mononuclear
hematopoietic cells. These cells were applied for the
experiments knowing that they respond to hIL-6 and
were shown to harbor on their cell membrane the hIL-6
receptor a (gp80) and b (gp130) (Peters et al., 1998). As
a first step to this end we had developed an in vitro
infection assay by incubating human lymphocytes in vitro
with HBV-positive sera (Fig. 7). The amount of HBV in-
creased until day 7 and decreased later on. In this
infection system we were able to detect HBV ccc DNA.
We were not able to detect HBsAg in these cells, a
similar result to previous reported studies assessing
HBV replication in mononuclear hematopoietic cells from
HBV DNA-positive patients (Korba et al., 1986; Laskus et
al., 1997, 1999). The supplementation of hIL-6 to the
infection process facilitated the infection of lymphocytes
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ossibly to a higher level.
Although the exact role of hIL-6 in HBV infection could
ot be determined from the results of this study, it could
e speculated that hIL-6 might serve as a bridge for viral
nternalization (Hibi et al., 1990; Rose-John et al., 1991), by
interacting with HBV (Neurath et al., 1992), and with the
FIG. 6. Liver histology of a HepG2-hIL-6R tumor that developed 1 mo
staining).
FIG. 7. Infection of human lymphocytes with HBV. Human lymphoc
cytokine. Cells were kept in culture in the presence of PHA and IL-2. HBV incu
RC and ccc HBV DNA species were analyzed in the cells.hIL-6Rb subunit gp130, through a membrane-anchored
hIL-6Ra subunit (gp80) (Kalai et al., 1997) or the secretory
IL-6R (shIL-6R) that later interacts with gp130 (Cichy et
l., 1996; Mackiewicz et al., 1992; May et al., 1992; Som-
rs et al., 1997). On the other hand, direct interaction
etween hIL-6 and the gp130 membrane glycoprotein
as also been reported (D’Alessandro et al., 1993) and
lowing intrasplenic injection into a SCID . BNX chimeric mice (H & E
re incubated in the presence of hIL-6 or without the addition of thenth folytes we
bation was also conducted in the presence of the superagonist HIL-6.
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305HBV INFECTION IN VIVOcould serve as another mode of attachment of HBV to the
host cell. Alternatively, hIL-6 could mediate the activation
of Jak-Tyk and STAT family protein kinases (Cressman et
al., 1996; Lutticken et al., 1994; Narazaki et al., 1994; Stahl
et al., 1994; Zhong et al., 1994) or the expression of
various cellular proteins (Caldenhoven et al., 1994; Suto
t al., 1993), that further increase the expression of an
nidentified membrane receptor or ligand, respectively,
hus facilitating HBV infection. Hyper-IL-6 is a superago-
ist to hIL-6 and as such increases the effect of this
ytokine on hepatocytes in vitro (.100 fold) as well as in
ivo (Maione et al., 1998). The result that the hyper-IL-6
HIL-6) superagonist molecule inhibited HBV infection in
itro supports the possibility that the hIL-6Ra is essential
in the physical interaction between that virus and the cell
membrane, i.e., a direct effect. In case that HBV infection
was enhanced by HIL-6, we were not able to suggest if
it was a direct or an indirect effect.
Our working hypothesis on the possible relationship
between the hIL-6 signal transduction system and HBV
infection is illustrated in Fig. 8. Based on this hypothesis
various modes of antiviral strategies could be employed.
The interaction of hIL-6 with gp80 or gp130 could be
blocked by peptides derived from gp80 or gp130 (Fig. 8,
A1 and A2) and hIL-6 amino acid sequence (Fig. 8, C1,
C2, and C3) or from those competing with hIL-6 interac-
FIG. 8. Illustration of the possible interactions between HBV and hIL
n a direct or indirect mode. (Option I) HBV first interacts with hIL-6; this
ype (hIL-6Ra), or the secretory type (shIL-6Ra). In both cases the viral–
II) hIL-6 through a signal transduction mechanism up-regulates an unk
through D are potential site for antiviral agents to interfere with viral etion with pre-S1 (Fig. 8, B). Conjugating hIL-6 with variouscomponents that could suppress HBV interaction with
any molecule involved in the attachment to the cell mem-
brane is also possible (Fig. 8, D).
A different possibility to the role of hIL-6 in HBV infec-
tion would be that when the virus buds from the infected
cells it incorporates the hIL-6Ra into the viral envelope
nd through this integration enables the direct binding of
IL-6 with the virus on one side and the hepatocyte at the
ther.
Additional experiments are needed to further elucidate
he exact role of hIL-6, hIL-6R, shIL-6R, and gp130 in HBV
nfection. Once the early steps of viral infection, including
ritical factors involved in cell membrane attachment, are
nfolded, new additional, antiviral strategies could be
eveloped.
MATERIAL AND METHODS
Chimeric animals (Trimera mice). We have recently
hown that a chimeric mouse, generated by using Beige/
ude/X linked immunodeficient (BNX) mice precondi-
ioned by total body irradiation (12 Gy) and reconstituted
ith severe combined immunodeficient (SCID) mice
one marrow (BM) cells, is permissive for normal human
and B cells (Lubin et al., 1991), as well as for normal
hypothesis argues that hIL-6 is a potential mediator for HBV infection
x later finds the receptor for hIL-6 (gp80), the cell membrane-anchored
r complex attaches to the gp130 protein on the cell membrane. (Option
actor to be expressed at the cell surface to enable viral attachment. A
cells.-6. This
comple
receptohuman liver tissue (Galun et al., 1995). HCV viremia was
wp
p
p
C
w
a
e
a
n
w
s
m
H
w
o
p
c
M
w
7
s
p
t
w
1
p
H
r
i
s
b
t
1
p
p
1
r
o
w
m
f
306 GALUN ET AL.detectable for up to 2 months after implantation under
the kidney capsule of the BNX . SCID chimeric animals
of either a human liver fragment with preexisting HCV
infection or normal human liver tissue, incubated ex vivo
with HCV-positive sera (Galun et al., 1995). Recently we
ere also able to establish the HBV in vivo infection
model in Trimera mice (Ilan et al., 1999). This animal
model was applied for the experiments described in this
report.
HBV infection protocol. We have recently described
our HBV infection model using chimeric animals (Ilan et
al., 1999). In brief, small fragments (1–3 mm3) of normal
human liver from a patient with no evidence of any
HBV-related markers or disease (HBsAg and anti-HBc
negative as well as HBV DNA by PCR negative) were
selected for the experiments. Liver fragments were incu-
bated ex vivo with 400 ml of a high-titer HBV DNA-
ositive serum (.107 particles/ml) in 1 ml DMEM sup-
lemented with 2 mg/ml polybrene, in the absence or
resence of hIL-6 (500 ng/ml), for 24 h at 37°C, in a 5%
O2 incubator. In each experiment described all groups
of mice were infected with the same HBV infectious sera.
After treatment, the liver fragments were repeatedly
washed with DMEM and transplanted under the kidney
capsule of chimeric animals. Blood was collected retro-
bulbarly from each mouse, and 100 ml of serum samples
as treated with 0.5 mg/ml proteinase K in 10 mM EDTA
nd 0.25% SDS for 2 h at 55°C or overnight at 37°C and
xtracted twice with phenol, once with phenol–CHCl3,
nd once with CHCl3. DNA was precipitated with etha-
ol, using 0.1 vol 5 M NaCl and a DNA microcarrier. DNA
as dissolved in 30 ml Tris–EDTA, pH 8.0, and was
ubjected to PCR amplification.
In an alternative infection protocol a fragment of nor-
al human liver from a patient with no evidence of any
BV-related markers of disease was infected ex vivo
ith hepatitis B virus. Small (1–3 mm3) liver fragments
were incubated with 1 ml human serum containing ;108
HBV particles and 3 mg polybrene for 1.5 h at 37°C. To
test the effect of IL-6 we added into the infection mixture
500 ng of rhIL-6 (van Dam et al., 1993). In experiments
designed to neutralize intrinsic IL-6 effects, the infection
mixture was preincubated for 2 h at 25°C with 50 mg of
monoclonal anti-human IL-6 antibody (Cat. No. MAB 206,
R&D Systems Inc., Minneapolis, MN) in the absence of
added IL-6, before the incubation with the liver tissue.
Detection of HBV sequences in chimeric mouse se-
rum. HBV sequences were detected by PCR using 20 ml
f serum in 50 ml PCR reaction volume containing 10
mol of each oligonucleotide primer in reaction buffer
ontaining 10 mM Tris–HCl, pH 8.3; 50 mM KCl; 2.0 mM
gCl2; 0.01% (w/v) gelatin; 250 mM dATP, dGTP, dCTP,
and TTP; and 0.5 U of Taq polymerase (Promega, Madi-
son, WI). The reaction mixtures were overlaid with 30 ml
of mineral oil. PCR cycles included 94°C for 1 min, 55°C
for 1 min, and 72°C for 3 min, 35 repeated cycles.Oligonucleotides used for the precore/core amplification:
oligo 1, sense (nt 1778 to 1806) 59-GGAGGCTGTAG-
GCAAAATTGGTCTGCGC-39; oligo 2, antisense (nt 2446
to 2408) 59-CCCGAGATTGAGATCTTCTGCGACGCG-
GCGATT-GAG-ACC-39. The sequence originated from an
adw subtype; nt numbering starts from EcoRI site. The
expected size of the PCR DNA product is 668 bp. The
PCR samples were run on a 2% agarose gel, transferred
to a nylon membrane (Biodynea), and hybridized with a
32P-radioactive nick-translated probe. The autoradiogram
as exposed, with intensifying screens, at 270°C for
h. In order to confirm the PCR results, the mice serum
amples were also subjected to PCR amplification with
rimers spanning the envelope gene region and showed
he same results (data not shown). Reproducible results
ere obtained from similar experiments. There were
0–20 mice in each experimental group. Part of the ex-
eriments described were assessed by applying a short
BV DNA sequence detection system which we have
ecently developed (Klein et al., 1997). In brief, HBV DNA
was extracted from 100 ml of mouse serum that was
ncubated in 400 ml of extraction solution (0.25% SDS, 5
mM EDTA, 10 mM Tris–HCl, pH 8, 250 mg/ml proteinase
K) for 2.5 h at 65°C. A total of 100 ml of 5mg/ml of bovine
erum albumin (BSA) solution was then added, followed
y phenol/chloroform extraction and ethanol precipita-
ion. DNA was collected, dried, and resuspended in 50 ml
H2O. PCR was performed using the same core primers in
00 ml of a PCR mixture containing 13 Taq polymerase
buffer (Promega), 2.5 mM MgCl2, 0.2 mM each dNTP, 50
mol of each primer, 1 mg/ml BSA, and 0.5 U of Taq
olymerase. The PCR reaction was carried for 32 cycles,
min at 94°C, 1.5 min at 55°C, and 2 min at 72°C. The
eaction was ended with 10 min at 72°C. Fifty microliters
f the PCR mixture was dot-blotted and then hybridized
ith a 32P-labeled DNA fragment corresponding to nu-
cleotides 1866–2290 of the core sequence, followed by
exposure to an X-ray film.
To prevent PCR product contaminations, the extraction
of DNA and analysis of PCR products were preformed in
separate rooms by different personnel. All known enzy-
matic agents were UV illuminated prior to use for over 10
min. All samplings were conducted using filtered tips.
Determination of HBV ccc DNA in engrafted liver frag-
ments. The method for the specific detection HBV ccc
DNA was previously reported by Kock and Schlicht
(1993) and Mason et al. (1998). We have applied this
ethod with minor modifications. DNA was extracted
rom liver fragments (3 mm3 each), using the DNAzol-BD
reagent (Molecular Research Center Inc., Cincinnati, OH)
(Lubin et al., 1991) and resuspended in 100 ml of H2O.
Fifty microliters was subjected to PCR using the 59-end
primer 59-CCTCTGCCGATCCATACTGCGGAAC-39 (HBV
nucleotides 1257–1282, S2), chosen from within the HBV
particle (1) strand deleted region, and the 39-end primer
59-GCTTGCCTGAGTGCAGTATGG-39 (HBV nucleotides
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307HBV INFECTION IN VIVO2075–2055, AS2). PCR was performed in a 100-ml reac-
ion mixture containing 13 Taq polymerase buffer, 2.5
M MgCl2, 0.2 mM each dNTP, 50 pmol of each primer,
1 mg/ml BSA, and 2.5 U of Taq polymerase (Promega).
The PCR reaction was programmed for 2 min at 94°C
and then 30 cycles, 1 min at 94°C and 3 min at 72°C. The
final elongation reaction was 5 min at 72°C. Analysis on
1.5% agarose gel results in a 820-bp band. The gel was
further analyzed by sequencing and by dot blot hybrid-
ization, using the 32P-labeled 424-bp DNA fragment cor-
responding to nucleotides 1866–2290 of the core se-
quence.
Immunohistochemistry. Paraffin-embedded tissues
were cut into 4- to 6-mm-thick sections, deparaffinized in
ylene and alcohol, and placed for 15 min in alcohol–
2O2 for blocking endogenous peroxidase. Slides were
thoroughly washed with tap water and transferred to
PBS. Sections were then treated with BSA to prevent
background staining and incubated for 1 h with a primary
murine anti-HBs antibody (Zymed Lab, Inc., San Fran-
cisco, CA) at room temperature, in a humidified chamber.
Slides were rinsed with PBS for 3 min and incubated with
a biotinylated linked goat anti-mouse antibody for 30 min
and with the labeling reagent peroxidase-conjugated
streptavidin (Biogenex StrAvigen, from San Ramon, CA),
for 30 min. After rinsing, the peroxidase label was dem-
onstrated using 3-amino-9-ethylcarbazol (AEC) for 15
minutes and counterstained with Mayer hematoxylin.
AEC produced a red product that is soluble in alcohol
and is used with an aqueous mounting medium (Kaiser’s
glycerol gelatin). A negative control was run using the
same technique, but omitting the primary antibody and
adding the streptavidin–biotin complex. Liver biopsy from
a HBV-infected patient, with high-titer HBV DNA and
HBsAg in serum, was used as a positive control.
Incubation of HepG2-derived cells with HBV in the
presence or absence of hIL-6. To further assess the role
of hIL-6 in supporting HBV infection, a human hepato-
blastoma cell line HepG2 (ATCC HB 8065), a HepG2-
derived, stably transfected hIL-6Ra (gp80) cell line
(HepG2-hIL-6Ra) and a null hIL-6R (a cell line which
oes not express hIL-6Ra) named HepG2-PDI (Rose-
John et al., 1993), were incubated with HBV DNA-positive
sera, with or without hIL-6. It is important to indicate that
all cell lines do express the IL-6Rb (gp130), including the
epG2-PDI cells probably at a similar level; the HepG2
ells express also the IL-6Ra although at a lower level
han the HepG2-hIL-6Ra cells. Cells were grown as a
monolayer culture in DMEM supplemented with 10%
fetal bovine serum. For infection experiments, cells were
trypsinized, washed with PBS, and incubated with HBV-
positive human sera (108 particles/ml), in the presence or
bsence of hIL-6 (500 ng/ml), in a total volume of 1 to 2
l. After 2 to 4 h, 2 3 106 cells were injected intrasplen-
cly to chimeric mice to generate hepatoblastoma foci in
he liver. Animals were splenectomized following the 2njection. Mice were bled at day 13. DNA was extracted
rom 100 ml sera and subjected to PCR amplification. All
groups of mice were infected with the same HBV infec-
tious sera.
Long-term human mononuclear culture. Human blood
was withdrawn in Li21–heparin collecting tubes from
ealthy donors. Serum samples from these donors were
ssessed for HBV serological and virological markers
ncluding HBV DNA by PCR as well as for HCV markers.
ll samples used in the experiments described were
ound negative for these viral markers including anti-HBc
ntibodies. Mononuclear cells were separated from
0–40 ml of blood by Ficoll–Hypaque sedimentation gra-
ient, centrifuged at 800 g for 35 min at 20°C. Cells were
ollected and washed two times with RPMI 1640 medium
ontaining 10% FCS, glutamine, and antibiotics (penicillin
nd streptomycin). Cells were used for infection experi-
ent, in part from fresh separation samples and in part
rom frozen samples stored in liquid nitrogen. Cells were
ultured in the same separation medium and additives
ontaining 2 mg/ml of phytohemagglutinin (PHA), 20 U/ml
of human IL-2, at 37°C with 5% CO2. After 3 days, mono-
uclear cells were infected with HBV sera as will be
escribed later. Following infection the culture medium
as supplemented with PHA and IL-2 every 3 culture
ays. Cells were kept in culture for 21 days and over
sing these conditions.
HBV infection protocol human mononuclear cells. Hu-
an sera were screened for the presence of HBV DNA
equences. Positive sera were analyzed quantitatively
or viral particle concentration as we have described
efore (Klein et al., 1997). Sera containing over 108 par-
icles per milliliter were selected for infection experi-
ents. For each infection experiment between 5 3 106 to
107 PMNC were used. The infection experiments in-
luded the following groups: (Group 1) Cells were incu-
ated with HBV without the addition of hIL-6 in the
resence of 2 mg/ml polybrene, for 90 min at 37°C, in a
% CO2 shaking incubator, in a total volume of 1.5 to 2 ml.
Group 2) Cells were incubated with 1 ml of HBV-positive
erum, in the presence of hIL-6 (500 ng/ml) and 2 mg/ml
olybrene, for 90 min at 37°C, in a 5% CO2 shaking
incubator, in a total volume of 1.5 to 2 ml. (Group 3) Cells
were incubated with 1 ml of HBV-positive serum, in the
presence of the designer cytokine HIL-6, 1.5 mg/ml,
which was recently produced by one of the investigators
of this study (Fischer et al., 1997; Rakemann et al., 1999;
Schirmacher et al., 1998) and 2 mg/ml polybrene, for 90
min at 37°C, in a 5% CO2 shaking incubator, in a total
olume of 1.5 to 2 ml. Following incubation of the viral
IL-6 or viral HIL-6 mixtures, the cells were intensively
ashed three times with F-12 medium. Cell were contin-
ously incubated in RPMI medium supplemented with
0% FCS, PHA, and hIL-2 as described above. Cells were
arvested for HBV DNA extraction every 3 days up to day
1 following infection.
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